Anxiety / depression / mood
Dysregulated GABAergic/monoaminergic tone and stress physiology.
Decision support, not prescription. You decide.
Candidate agents
6 agents · tap to expandInositolInositol is a well-tolerated glucose isomer with a modest, mostly sub-threshold human signal in depression and PMDD mood symptoms; treat it as a low-risk adjunct with unproven stand-alone efficacy, not a primary antidepressant.
Inositol is a well-tolerated glucose isomer with a modest, mostly sub-threshold human signal in depression and PMDD mood symptoms; treat it as a low-risk adjunct with unproven stand-alone efficacy, not a primary antidepressant.
Full clinical story
As a precursor of the phosphatidylinositol second-messenger system, inositol is proposed to normalize downstream signaling of serotonergic (5-HT2) and other monoaminergic receptors implicated in mood and panic, offering a rationale distinct from direct receptor agonism.
Emerging but weak. A meta-analysis of double-blind RCTs (n=242 depression, n=70 anxiety) found no statistically significant benefit overall, though inositol produced marginally more responders in depression (p=0.06) and a trend in PMDD (p=0.07), and did not separate from placebo for anxiety/OCD; a separate small crossover RCT (n=20) found inositol at least comparable to fluvoxamine for panic-attack frequency over one month. The 'emerging' grade reflects that human data exist but are small and largely fall short of significance.
Anecdotal community signal only: patients (often in PMDD, anxiety, and 'natural alternative to SSRI' circles) take high-dose myo-inositol powder dissolved in water, frequently stacked with SSRIs or used during PMS luteal windows, and report calmer mood and fewer panic episodes. This is uncontrolled self-report, not evidence of efficacy, and reporting bias is high in supplement forums.
For context only: trials used roughly 12-18 g/day of myo-inositol, typically divided; community use often mirrors this range but tolerability is limited by dose.
Main condition-specific flags are additive serotonergic effect when combined with SSRIs (theoretical, generally mild), possible mood destabilization/switch in bipolar depression, and dose-dependent GI upset (loose stool, nausea) that reduces adherence at effective doses.
A cheap, benign option with a real but modest and largely sub-threshold human signal concentrated in depression and PMDD; reasonable as an adjunct for motivated patients, but clinicians should not expect it to replace established antidepressants and should set modest expectations.
PE-22-28PE-22-28 (mini-spadin) is a selective TREK-1 blocker with fast antidepressant-like effects in rodents - but zero human evidence.
PE-22-28 (mini-spadin) is a selective TREK-1 blocker with fast antidepressant-like effects in rodents - but zero human evidence.
Full clinical story
Blocks the TREK-1 background potassium channel (IC50 ~0.12 nM), a target whose genetic deletion confers a depression-resistant phenotype; downstream it potentiates serotonergic signaling and raises hippocampal CREB phosphorylation. It is a shortened, more stable analog of the natural peptide spadin.
Preclinical only. In mice, PE-22-28 and analogs reduced immobility in the forced-swim test and cut latency-to-eat in novelty-suppressed feeding after a 4-day course, with better TREK-1 affinity and ~23 h in vivo stability vs spadin's ~7 h (PMID 28955242). The concept traces to Mazella et al.'s spadin work (PMID 20405001) and is reviewed in PMID 30291907. There are NO human clinical trials.
Sparse. A LongeCity thread discusses spadin/PE-22-28 as a fast-acting TREK-1 antidepressant and sourcing options, but contains no verified first-hand user experience or self-reported dosing. Reddit is not accessible.
No established or approved human dose exists; all data are rodent parenteral (intraperitoneal) dosing. Do not extrapolate animal doses to humans.
Contraindicated in bipolar disorder (pro-neurogenic, excitability-increasing TREK-1 blockade may destabilize mood cycling or trigger mania) and in cardiac arrhythmia or people taking antiarrhythmic / potassium-channel drugs. No human safety data of any kind. Research use only.
Mechanistically compelling and preclinically promising as a fast antidepressant and neurogenesis stimulant, but PE-22-28 remains an unproven research chemical with no human efficacy or safety data - experimental only, and to be avoided in bipolar or arrhythmia patients.
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
- Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design
- Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin
- Mixed1 corroboratinganecdotal
Informational forum discussion of spadin/PE-22-28 as a fast-acting TREK-1-blocking antidepressant; interest in sourcing the peptide but no verified first-hand user experience reports or self-reported dosing.
No peer data yet. Aggregates appear once ≥3 clinicians log an outcome.
OxytocinIntranasal oxytocin is an investigational add-on for mood/distress with one positive small inpatient RCT whose benefit was concentrated in women; take it as a hypothesis-generating adjunct signal, not established therapy.
Intranasal oxytocin is an investigational add-on for mood/distress with one positive small inpatient RCT whose benefit was concentrated in women; take it as a hypothesis-generating adjunct signal, not established therapy.
Full clinical story
Oxytocin modulates central stress physiology — dampening HPA-axis/amygdala reactivity and enhancing social-affiliative and therapeutic-alliance processes — which provides a plausible route to reduced depression and general distress rather than a direct monoaminergic mechanism.
Emerging. A double-blind placebo-controlled RCT (N=87 inpatients) of intranasal oxytocin 32 IU twice daily for 4 weeks added to usual care showed greater improvement in depression and general distress but no effect on anxiety or working alliance; a secondary analysis found the benefit was driven almost entirely by female patients. Single small trial with sex-moderated effects — grade honestly remains 'emerging.'
Anecdotal community signal only: oxytocin nasal sprays are used off-label for social anxiety, bonding, low mood, and postpartum contexts, with users reporting transient warmth, reduced social stress, and improved connectedness. These are uncontrolled self-reports; effects are described as short-lived and highly context/expectation dependent, and are not evidence of durable antidepressant action.
For context only: the supporting trial used 32 IU intranasally twice daily for 4 weeks; community intranasal dosing is variable and often lower and as-needed.
Condition-specific flags: benefit appears sex-dependent (weaker or absent in males), effects on anxiety specifically were null, and social/emotional effects can be context-dependent or even negative in some interpersonal settings; caution in pregnancy given uterotonic activity.
A biologically plausible adjunct with a single supportive inpatient RCT and a notable female-predominant response; worth watching and reasonable to consider adjunctively in select cases, but far from a validated stand-alone treatment.
N-Acetyl Selank AmidateSelank is a synthetic tuftsin-analog peptide marketed for anxiety on the strength of rodent data only; treat its anxiolytic claim as preclinical and unproven in controlled human trials.
Selank is a synthetic tuftsin-analog peptide marketed for anxiety on the strength of rodent data only; treat its anxiolytic claim as preclinical and unproven in controlled human trials.
Full clinical story
In animal models Selank shows benzodiazepine-comparable anxiolytic activity and is described as modulating GABAergic tone (alongside effects on enkephalin degradation and monoamine/BDNF systems), fitting the condition's GABAergic lever — but the human relevance of these mechanisms is not established.
Preclinical. The anxiolytic evidence rests on rat models — e.g., Selank reducing anxiety in unpredictable chronic mild stress and augmenting diazepam's effect on the elevated plus maze — with no adequately powered, peer-reviewed double-blind human RCT confirming efficacy. A pharmacology review explicitly notes Selank is poorly studied and sold to consumers as a supplement despite thin data. Grade 'preclinical' is correct.
Anecdotal community signal only: nootropic and biohacker communities use Selank as a subcutaneous/intranasal peptide for acute anxiety, stress, and 'take-the-edge-off' effects without benzodiazepine sedation or dependence, reporting rapid calming that fades over hours. These are uncontrolled self-reports, not evidence of efficacy; product purity and dosing from gray-market sources are unverified.
For context only: community intranasal/subcutaneous use is commonly cited around 250-500 mcg per dose, once or a few times daily in short courses — this is not a validated protocol.
Condition-specific flags: it is a GABAergic agent that may be additive with benzodiazepines, alcohol, and other CNS depressants; it is sold as an unregulated supplement/research chemical with no human safety dataset, and reviews group it with phenibut among under-studied GABAergic agents of concern.
Mechanistically interesting and popular off-label, but the anxiolytic case is animal-only; clinicians should treat human efficacy and long-term safety as unestablished and source/quality as a real risk.
SemaxSemax is a synthetic ACTH(4-10) peptide with anxiolytic/antidepressant signals in stressed rodents only; treat its mood claim as preclinical, with no controlled human mood-disorder trials.
Semax is a synthetic ACTH(4-10) peptide with anxiolytic/antidepressant signals in stressed rodents only; treat its mood claim as preclinical, with no controlled human mood-disorder trials.
Full clinical story
In animals Semax normalizes brain monoamine (serotonin/dopamine/noradrenaline) levels and stress-related behavior and raises BDNF, aligning with the condition's monoaminergic/stress-physiology lever — but notably it acted only under elevated-stress conditions, not in normal-state animals.
Preclinical. Evidence is rodent behavioral: Semax reversed CCK-4-induced anxiety- and depression-like behavior in the elevated plus maze and forced swim test, and attenuated behavioral and monoamine disturbances from neonatal SSRI (fluvoxamine) exposure. There are no peer-reviewed double-blind human RCTs for depression or anxiety; grade 'preclinical' is accurate.
Anecdotal community signal only: nootropic users take intranasal Semax for focus, mood lift, and stress resilience, often stacked with Selank, reporting subtle antidepressant/anti-anxiety and cognitive effects. These are uncontrolled reports on gray-market product, not evidence of efficacy; effects are described as mild and easily confounded with placebo.
For context only: community intranasal use is commonly cited around 250-600 mcg/day (and higher for the N-acetyl 'Semax amidate' variant); no validated mood-disorder dosing exists.
Condition-specific flags: theoretical additive/serotonergic interaction given its monoaminergic effects, unregulated supplement sourcing with no human safety data in mood disorders, and effects that appear stress-condition-dependent, making benefit in euthymic or mildly symptomatic patients uncertain.
A plausible neuromodulatory peptide with encouraging animal mood data but zero controlled human mood evidence; interesting to track, not something to present to patients as a proven antidepressant or anxiolytic.
Not recommended for this condition
Shown to close the loop · the evidence points the wrong way here.
SemaglutideFor mood, semaglutide carries a known-negative safety signal, not a therapeutic one: observational data associate GLP-1 receptor agonist exposure with later antidepressant dispensing, so monitor mood rather than use it to treat it.
For mood, semaglutide carries a known-negative safety signal, not a therapeutic one: observational data associate GLP-1 receptor agonist exposure with later antidepressant dispensing, so monitor mood rather than use it to treat it.
Full clinical story
The signal is association-level; a mechanistic route through GLP-1 effects on central reward, appetite, and stress circuits is plausible but unproven, and confounding by indication (weight, diabetes, cardiometabolic burden — themselves linked to depression) cannot be excluded in these data.
Emerging safety signal. A large Australian pharmacoepidemiologic study (PBS data) found GLP-1 receptor agonist exposure, including semaglutide, associated with increased subsequent antidepressant dispensing (adjusted HR 1.19; cross-sectional ORs ~1.44-1.52). This is observational, dispensing-based, and cannot establish causation; grade 'emerging' with an 'adverse' direction is the honest characterization.
Anecdotal community signal only: within weight-loss and GLP-1 patient communities there are mixed reports — some describe low mood, anhedonia, or loss of the 'food reward' pleasure, while others report improved mood with weight loss. These conflicting self-reports underscore uncertainty and should not be read as confirming or refuting the pharmacoepidemiologic signal.
Not applicable as a mood therapeutic — there is no antidepressant dosing. In practice semaglutide is dosed for its metabolic indications; mood is a monitoring parameter, not a titration target.
Condition-specific flags: exercise vigilance for new or worsening depression and mood change in patients started on semaglutide/GLP-1 agonists, particularly those with pre-existing psychiatric history; regulators and labels have flagged monitoring for depression and suicidal ideation, so screen at baseline and follow-up.
Treat this as a mood-safety watch item, not a treatment: the evidence is an observational association requiring vigilance, and clinicians should monitor mood in patients on semaglutide rather than expect or induce psychiatric benefit.
Matching protocol templates
Browse allStaggered hunger control, cost reduction, side effect modulation
Mood normalization, sleep enhancement, and stress resilience
Mood stabilization and executive function support
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment · the licensed clinician orders labs, writes notes, and prescribes.